| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Heart Failure | 66 | 2020 | 6638 | 4.71 | Why? |
| Shock, Cardiogenic | 13 | 2020 | 700 | 2.11 | Why? |
| Diuretics | 6 | 2019 | 326 | 1.29 | Why? |
| Hemodynamics | 13 | 2020 | 1562 | 1.08 | Why? |
| Stroke Volume | 15 | 2019 | 2153 | 1.05 | Why? |
| Cardiomyopathies | 6 | 2019 | 997 | 1.05 | Why? |
| Cardiovascular Agents | 3 | 2017 | 663 | 0.98 | Why? |
| Natriuretic Peptide, Brain | 9 | 2019 | 1215 | 0.96 | Why? |
| Acute Disease | 27 | 2019 | 6029 | 0.95 | Why? |
| Cardiology | 11 | 2020 | 2873 | 0.94 | Why? |
| Societies, Medical | 13 | 2020 | 6907 | 0.93 | Why? |
| Burns | 8 | 2019 | 466 | 0.92 | Why? |
| Vasoconstrictor Agents | 8 | 2020 | 714 | 0.91 | Why? |
| Relaxin | 2 | 2018 | 25 | 0.91 | Why? |
| Puerperal Disorders | 3 | 2019 | 151 | 0.90 | Why? |
| Atrial Natriuretic Factor | 3 | 2018 | 75 | 0.90 | Why? |
| CD146 Antigen | 2 | 2018 | 19 | 0.88 | Why? |
| Cardio-Renal Syndrome | 2 | 2018 | 68 | 0.82 | Why? |
| Peripartum Period | 5 | 2019 | 89 | 0.72 | Why? |
| Lactic Acid | 2 | 2020 | 393 | 0.69 | Why? |
| Consensus Development Conferences as Topic | 1 | 2017 | 93 | 0.66 | Why? |
| Forearm | 1 | 2016 | 52 | 0.65 | Why? |
| Placenta Growth Factor | 1 | 2017 | 93 | 0.65 | Why? |
| Patient Care Bundles | 1 | 2019 | 137 | 0.65 | Why? |
| Bronchodilator Agents | 2 | 2019 | 444 | 0.65 | Why? |
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2017 | 120 | 0.64 | Why? |
| Coronary Sinus | 1 | 2016 | 41 | 0.64 | Why? |
| Adrenomedullin | 4 | 2020 | 217 | 0.62 | Why? |
| Disease Management | 7 | 2020 | 6841 | 0.61 | Why? |
| Renal Replacement Therapy | 4 | 2020 | 1530 | 0.61 | Why? |
| Norepinephrine | 4 | 2019 | 152 | 0.60 | Why? |
| Cardiology Service, Hospital | 2 | 2020 | 602 | 0.59 | Why? |
| Cardiac Resynchronization Therapy | 1 | 2017 | 191 | 0.58 | Why? |
| Myocardial Infarction | 4 | 2018 | 3361 | 0.57 | Why? |
| Heart Ventricles | 3 | 2018 | 1139 | 0.56 | Why? |
| Research Report | 1 | 2018 | 376 | 0.54 | Why? |
| Blood Chemical Analysis | 1 | 2018 | 541 | 0.53 | Why? |
| Atrial Fibrillation | 2 | 2018 | 2320 | 0.52 | Why? |
| Vasodilator Agents | 1 | 2017 | 344 | 0.52 | Why? |
| Neovascularization, Pathologic | 1 | 2017 | 305 | 0.51 | Why? |
| Patient Discharge | 8 | 2019 | 5696 | 0.51 | Why? |
| Heart-Assist Devices | 2 | 2018 | 812 | 0.50 | Why? |
| Mineralocorticoid Receptor Antagonists | 3 | 2017 | 203 | 0.45 | Why? |
| Registries | 15 | 2020 | 12327 | 0.45 | Why? |
| Biomarkers | 21 | 2019 | 23361 | 0.44 | Why? |
| Survival Rate | 15 | 2020 | 9206 | 0.44 | Why? |
| Hospital Mortality | 12 | 2019 | 22087 | 0.43 | Why? |
| Acute Kidney Injury | 11 | 2020 | 5762 | 0.42 | Why? |
| Time Factors | 22 | 2020 | 31397 | 0.42 | Why? |
| Organ Dysfunction Scores | 1 | 2017 | 1475 | 0.42 | Why? |
| Cardiac Output | 4 | 2020 | 183 | 0.41 | Why? |
| Ventricular Function, Left | 6 | 2018 | 1555 | 0.41 | Why? |
| Sepsis | 6 | 2021 | 3517 | 0.41 | Why? |
| Prospective Studies | 37 | 2021 | 43301 | 0.40 | Why? |
| Pulmonary Disease, Chronic Obstructive | 5 | 2019 | 3832 | 0.39 | Why? |
| Vascular Diseases | 1 | 2018 | 846 | 0.39 | Why? |
| Dyspnea | 3 | 2019 | 3847 | 0.38 | Why? |
| Critical Illness | 13 | 2021 | 17281 | 0.38 | Why? |
| Europe | 22 | 2020 | 12702 | 0.38 | Why? |
| Diagnostic Imaging | 1 | 2017 | 1044 | 0.37 | Why? |
| Acute Coronary Syndrome | 3 | 2018 | 2107 | 0.35 | Why? |
| Emergency Service, Hospital | 10 | 2020 | 14232 | 0.35 | Why? |
| Proteomics | 2 | 2019 | 2481 | 0.35 | Why? |
| Epinephrine | 3 | 2018 | 323 | 0.35 | Why? |
| Interleukin-1 Receptor-Like 1 Protein | 2 | 2017 | 92 | 0.33 | Why? |
| Monitoring, Intraoperative | 2 | 2019 | 140 | 0.33 | Why? |
| Natriuretic Peptides | 2 | 2018 | 66 | 0.33 | Why? |
| Delivery of Health Care, Integrated | 1 | 2019 | 1549 | 0.33 | Why? |
| Humans | 124 | 2021 | 930598 | 0.32 | Why? |
| Multiple Organ Failure | 1 | 2017 | 1724 | 0.32 | Why? |
| Intensive Care Units | 19 | 2021 | 29594 | 0.32 | Why? |
| Blood Pressure | 6 | 2019 | 2198 | 0.31 | Why? |
| Aged | 60 | 2021 | 215776 | 0.30 | Why? |
| Adrenergic beta-Antagonists | 3 | 2018 | 465 | 0.30 | Why? |
| Proportional Hazards Models | 10 | 2020 | 6543 | 0.30 | Why? |
| Acinetobacter Infections | 2 | 2018 | 273 | 0.30 | Why? |
| Survivors | 1 | 2018 | 2619 | 0.29 | Why? |
| France | 11 | 2021 | 12074 | 0.29 | Why? |
| Peptide Fragments | 5 | 2019 | 2075 | 0.29 | Why? |
| Acinetobacter baumannii | 2 | 2018 | 378 | 0.29 | Why? |
| Ventricular Function, Right | 2 | 2019 | 388 | 0.29 | Why? |
| Pregnancy Complications, Cardiovascular | 2 | 2019 | 231 | 0.29 | Why? |
| Protein Precursors | 3 | 2018 | 425 | 0.29 | Why? |
| Female | 75 | 2021 | 380317 | 0.29 | Why? |
| Patient Readmission | 3 | 2019 | 1543 | 0.28 | Why? |
| Anesthesia, General | 3 | 2019 | 470 | 0.28 | Why? |
| Pulmonary Embolism | 2 | 2021 | 4775 | 0.27 | Why? |
| Oxygen Consumption | 2 | 2020 | 711 | 0.27 | Why? |
| Male | 72 | 2021 | 367725 | 0.27 | Why? |
| Critical Care | 7 | 2019 | 14081 | 0.27 | Why? |
| Shock, Septic | 2 | 2018 | 1313 | 0.26 | Why? |
| Monitoring, Physiologic | 4 | 2019 | 1956 | 0.26 | Why? |
| Length of Stay | 8 | 2019 | 11042 | 0.26 | Why? |
| Pneumonia, Bacterial | 2 | 2021 | 843 | 0.26 | Why? |
| Prognosis | 26 | 2019 | 32490 | 0.26 | Why? |
| Lipocalin-2 | 3 | 2018 | 156 | 0.25 | Why? |
| Multicenter Studies as Topic | 3 | 2019 | 2437 | 0.25 | Why? |
| Thermodilution | 2 | 2019 | 62 | 0.25 | Why? |
| Injections, Intravenous | 3 | 2018 | 381 | 0.24 | Why? |
| Mortality | 5 | 2019 | 7132 | 0.24 | Why? |
| Burn Units | 3 | 2019 | 179 | 0.24 | Why? |
| Randomized Controlled Trials as Topic | 3 | 2019 | 10649 | 0.24 | Why? |
| Growth Differentiation Factor 15 | 2 | 2019 | 89 | 0.23 | Why? |
| Receptors, Polymeric Immunoglobulin | 1 | 2021 | 19 | 0.23 | Why? |
| Percutaneous Coronary Intervention | 2 | 2018 | 3646 | 0.23 | Why? |
| Adrenal Cortex Hormones | 1 | 2019 | 6537 | 0.23 | Why? |
| Cardiotonic Agents | 2 | 2018 | 418 | 0.22 | Why? |
| Enkephalins | 2 | 2018 | 10 | 0.22 | Why? |
| Water-Electrolyte Imbalance | 2 | 2018 | 119 | 0.22 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2019 | 5277 | 0.21 | Why? |
| Aged, 80 and over | 27 | 2020 | 88759 | 0.21 | Why? |
| Pilot Projects | 5 | 2019 | 5182 | 0.21 | Why? |
| Propensity Score | 6 | 2018 | 2690 | 0.21 | Why? |
| Almitrine | 1 | 2020 | 35 | 0.21 | Why? |
| Treatment Outcome | 18 | 2021 | 51732 | 0.21 | Why? |
| Ventricular Dysfunction, Right | 2 | 2018 | 639 | 0.21 | Why? |
| Alkaline Phosphatase | 2 | 2019 | 257 | 0.20 | Why? |
| Middle Aged | 52 | 2021 | 270681 | 0.20 | Why? |
| Fluid Therapy | 3 | 2019 | 628 | 0.20 | Why? |
| Blood Flow Velocity | 2 | 2017 | 193 | 0.20 | Why? |
| Respiratory System Agents | 1 | 2020 | 63 | 0.20 | Why? |
| Critical Pathways | 2 | 2020 | 1587 | 0.19 | Why? |
| Liver Cirrhosis, Biliary | 1 | 2019 | 42 | 0.19 | Why? |
| Hyperbilirubinemia | 1 | 2019 | 81 | 0.19 | Why? |
| Recovery of Function | 3 | 2018 | 2461 | 0.19 | Why? |
| Heart Function Tests | 1 | 2019 | 101 | 0.19 | Why? |
| Oxidoreductases Acting on Sulfur Group Donors | 1 | 2018 | 9 | 0.19 | Why? |
| Acetazolamide | 1 | 2018 | 27 | 0.19 | Why? |
| Cohort Studies | 13 | 2021 | 36005 | 0.19 | Why? |
| Angiotensin Receptor Antagonists | 4 | 2019 | 3892 | 0.18 | Why? |
| Hepcidins | 1 | 2018 | 97 | 0.18 | Why? |
| Hypotension | 2 | 2019 | 392 | 0.18 | Why? |
| Cholestasis | 1 | 2019 | 114 | 0.18 | Why? |
| Bromocriptine | 1 | 2017 | 42 | 0.18 | Why? |
| Bacteriological Techniques | 1 | 2020 | 239 | 0.18 | Why? |
| Follow-Up Studies | 12 | 2019 | 17020 | 0.17 | Why? |
| Pulmonary Edema | 2 | 2019 | 430 | 0.17 | Why? |
| Cholangitis, Sclerosing | 1 | 2019 | 106 | 0.17 | Why? |
| Capillary Permeability | 1 | 2019 | 277 | 0.17 | Why? |
| Neprilysin | 1 | 2018 | 112 | 0.17 | Why? |
| Practice Guidelines as Topic | 6 | 2019 | 15421 | 0.17 | Why? |
| Odds Ratio | 3 | 2018 | 5861 | 0.17 | Why? |
| beta-Lactam Resistance | 1 | 2018 | 150 | 0.17 | Why? |
| Hemodynamic Monitoring | 1 | 2017 | 61 | 0.17 | Why? |
| Microcirculation | 2 | 2019 | 447 | 0.16 | Why? |
| Hypoalbuminemia | 1 | 2019 | 235 | 0.16 | Why? |
| Morphine | 1 | 2017 | 71 | 0.16 | Why? |
| Echocardiography, Doppler | 1 | 2019 | 269 | 0.16 | Why? |
| Anesthetics, Inhalation | 1 | 2018 | 82 | 0.16 | Why? |
| Haptoglobins | 1 | 2017 | 117 | 0.16 | Why? |
| Intraoperative Complications | 1 | 2019 | 221 | 0.16 | Why? |
| Endotoxemia | 1 | 2018 | 143 | 0.16 | Why? |
| Hyperkalemia | 1 | 2017 | 140 | 0.16 | Why? |
| Anemia, Iron-Deficiency | 1 | 2018 | 210 | 0.16 | Why? |
| Checklist | 2 | 2019 | 714 | 0.16 | Why? |
| Early Medical Intervention | 1 | 2019 | 487 | 0.15 | Why? |
| Pulse Wave Analysis | 1 | 2017 | 221 | 0.15 | Why? |
| Conscious Sedation | 1 | 2018 | 222 | 0.15 | Why? |
| Noninvasive Ventilation | 3 | 2018 | 2329 | 0.15 | Why? |
| Solubility | 1 | 2016 | 382 | 0.15 | Why? |
| Serum Albumin | 1 | 2019 | 571 | 0.15 | Why? |
| Respiration, Artificial | 9 | 2021 | 22116 | 0.15 | Why? |
| Blood Proteins | 1 | 2019 | 551 | 0.15 | Why? |
| Kidney Function Tests | 3 | 2018 | 520 | 0.15 | Why? |
| Guideline Adherence | 2 | 2019 | 2309 | 0.15 | Why? |
| Positive-Pressure Respiration | 2 | 2020 | 1160 | 0.15 | Why? |
| Hypokalemia | 1 | 2017 | 195 | 0.15 | Why? |
| Glycopeptides | 1 | 2017 | 199 | 0.14 | Why? |
| Morbidity | 2 | 2018 | 1426 | 0.14 | Why? |
| Cardiomyopathy, Dilated | 1 | 2018 | 251 | 0.14 | Why? |
| Arterial Pressure | 1 | 2017 | 208 | 0.14 | Why? |
| Potassium | 1 | 2017 | 325 | 0.14 | Why? |
| Venous Thrombosis | 2 | 2020 | 2739 | 0.14 | Why? |
| Glomerular Filtration Rate | 2 | 2019 | 1262 | 0.14 | Why? |
| Survival Analysis | 4 | 2018 | 7592 | 0.14 | Why? |
| Candidemia | 1 | 2018 | 353 | 0.14 | Why? |
| Ventricular Remodeling | 1 | 2017 | 349 | 0.13 | Why? |
| Renin-Angiotensin System | 2 | 2020 | 3661 | 0.13 | Why? |
| Myocardial Ischemia | 1 | 2020 | 781 | 0.13 | Why? |
| Calcium Channel Blockers | 1 | 2017 | 367 | 0.13 | Why? |
| Vascular Stiffness | 1 | 2017 | 264 | 0.13 | Why? |
| Risk Factors | 19 | 2021 | 71621 | 0.13 | Why? |
| Immune System Diseases | 1 | 2018 | 410 | 0.13 | Why? |
| Cause of Death | 5 | 2017 | 4823 | 0.12 | Why? |
| Kinetics | 1 | 2021 | 3238 | 0.12 | Why? |
| Echocardiography | 4 | 2019 | 3661 | 0.12 | Why? |
| Iron | 1 | 2018 | 619 | 0.12 | Why? |
| Bacteria | 2 | 2021 | 1897 | 0.12 | Why? |
| Multivariate Analysis | 3 | 2020 | 5440 | 0.12 | Why? |
| Hospital Units | 1 | 2019 | 1017 | 0.12 | Why? |
| Multiplex Polymerase Chain Reaction | 1 | 2020 | 1439 | 0.12 | Why? |
| Pulmonary Artery | 1 | 2019 | 803 | 0.11 | Why? |
| Patients' Rooms | 1 | 2016 | 675 | 0.11 | Why? |
| Combined Modality Therapy | 2 | 2017 | 3395 | 0.11 | Why? |
| Linear Models | 1 | 2018 | 1914 | 0.11 | Why? |
| Heart | 2 | 2018 | 1791 | 0.11 | Why? |
| Belgium | 1 | 2018 | 2064 | 0.11 | Why? |
| Renal Dialysis | 2 | 2018 | 4358 | 0.11 | Why? |
| Hospitalization | 10 | 2020 | 54280 | 0.11 | Why? |
| Alanine Transaminase | 1 | 2017 | 1329 | 0.11 | Why? |
| Chi-Square Distribution | 3 | 2018 | 961 | 0.11 | Why? |
| Drug Resistance, Multiple, Bacterial | 1 | 2018 | 1115 | 0.10 | Why? |
| Risk Assessment | 7 | 2019 | 25439 | 0.10 | Why? |
| Observational Studies as Topic | 1 | 2018 | 1887 | 0.10 | Why? |
| Limit of Detection | 1 | 2018 | 2698 | 0.10 | Why? |
| Pregnancy | 5 | 2019 | 23879 | 0.10 | Why? |
| Paris | 3 | 2018 | 1287 | 0.10 | Why? |
| Health Care Costs | 1 | 2018 | 1007 | 0.10 | Why? |
| Molecular Targeted Therapy | 1 | 2018 | 1579 | 0.10 | Why? |
| Drug Prescriptions | 1 | 2018 | 1062 | 0.09 | Why? |
| Proteome | 1 | 2019 | 1812 | 0.09 | Why? |
| Dobutamine | 1 | 2008 | 36 | 0.09 | Why? |
| Ventilators, Mechanical | 1 | 2021 | 2193 | 0.09 | Why? |
| Global Health | 4 | 2020 | 13911 | 0.09 | Why? |
| Perioperative Care | 1 | 2019 | 1329 | 0.09 | Why? |
| Bacteremia | 1 | 2019 | 1372 | 0.09 | Why? |
| Creatinine | 3 | 2020 | 1443 | 0.09 | Why? |
| Plasma | 1 | 2018 | 1809 | 0.09 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 1261 | 0.09 | Why? |
| Congresses as Topic | 1 | 2018 | 1347 | 0.09 | Why? |
| Patient Care Management | 1 | 2019 | 1514 | 0.09 | Why? |
| Clinical Trials as Topic | 2 | 2018 | 7330 | 0.09 | Why? |
| Quality of Life | 2 | 2019 | 9820 | 0.09 | Why? |
| Half-Life | 2 | 2018 | 298 | 0.08 | Why? |
| Hypertension, Pulmonary | 1 | 2017 | 970 | 0.08 | Why? |
| Consensus | 2 | 2019 | 6345 | 0.08 | Why? |
| Disease Outbreaks | 3 | 2020 | 27595 | 0.08 | Why? |
| Double-Blind Method | 4 | 2018 | 5988 | 0.08 | Why? |
| Patient Care | 1 | 2018 | 1664 | 0.08 | Why? |
| Recombinant Proteins | 1 | 2017 | 3786 | 0.08 | Why? |
| Adult | 21 | 2021 | 244371 | 0.08 | Why? |
| Quality of Health Care | 1 | 2018 | 1948 | 0.08 | Why? |
| ROC Curve | 3 | 2018 | 6024 | 0.08 | Why? |
| Predictive Value of Tests | 2 | 2018 | 9537 | 0.07 | Why? |
| APACHE | 1 | 2008 | 682 | 0.07 | Why? |
| Hypoxia | 1 | 2020 | 3626 | 0.07 | Why? |
| Immunologic Factors | 1 | 2021 | 4206 | 0.07 | Why? |
| Spain | 6 | 2019 | 15545 | 0.07 | Why? |
| Statistics, Nonparametric | 2 | 2018 | 1008 | 0.07 | Why? |
| Diabetes Complications | 1 | 2017 | 2358 | 0.07 | Why? |
| Retrospective Studies | 13 | 2021 | 105322 | 0.07 | Why? |
| Dose-Response Relationship, Drug | 3 | 2018 | 3776 | 0.07 | Why? |
| Outpatients | 1 | 2017 | 3417 | 0.07 | Why? |
| Emergency Medical Services | 2 | 2017 | 3557 | 0.07 | Why? |
| Point-of-Care Systems | 1 | 2018 | 2955 | 0.07 | Why? |
| Incidence | 7 | 2021 | 25622 | 0.07 | Why? |
| Renal Insufficiency, Chronic | 1 | 2018 | 2654 | 0.06 | Why? |
| Patient Admission | 1 | 2020 | 5250 | 0.06 | Why? |
| Pneumonia | 2 | 2021 | 5652 | 0.06 | Why? |
| Ultrasonography | 1 | 2019 | 4409 | 0.06 | Why? |
| Stress Disorders, Post-Traumatic | 1 | 2019 | 2963 | 0.06 | Why? |
| Research Design | 1 | 2019 | 5830 | 0.06 | Why? |
| 12E7 Antigen | 1 | 2021 | 20 | 0.06 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.06 | Why? |
| Kidney Failure, Chronic | 1 | 2018 | 3222 | 0.06 | Why? |
| Inpatients | 1 | 2018 | 5161 | 0.06 | Why? |
| Disease Progression | 2 | 2017 | 13580 | 0.06 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.06 | Why? |
| Liver Diseases | 1 | 2017 | 2698 | 0.06 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.06 | Why? |
| Algorithms | 1 | 2018 | 7346 | 0.05 | Why? |
| Administration, Oral | 2 | 2018 | 2340 | 0.05 | Why? |
| Anti-Bacterial Agents | 2 | 2018 | 10083 | 0.05 | Why? |
| Partial Pressure | 1 | 2020 | 279 | 0.05 | Why? |
| Photoplethysmography | 1 | 2019 | 30 | 0.05 | Why? |
| Catheterization, Swan-Ganz | 1 | 2019 | 30 | 0.05 | Why? |
| Trauma Severity Indices | 1 | 2019 | 176 | 0.05 | Why? |
| Methods | 1 | 2018 | 19 | 0.05 | Why? |
| gamma-Glutamyltransferase | 1 | 2019 | 101 | 0.05 | Why? |
| Aldosterone | 1 | 2020 | 155 | 0.05 | Why? |
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2018 | 16 | 0.05 | Why? |
| Sarcoplasmic Reticulum | 1 | 2018 | 13 | 0.05 | Why? |
| Peroxiredoxins | 1 | 2018 | 13 | 0.05 | Why? |
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2018 | 33 | 0.05 | Why? |
| Propanols | 1 | 2018 | 4 | 0.05 | Why? |
| Transcription Factor CHOP | 1 | 2018 | 29 | 0.05 | Why? |
| Simplified Acute Physiology Score | 1 | 2018 | 102 | 0.05 | Why? |
| Plasma Volume | 1 | 2017 | 9 | 0.05 | Why? |
| Catheters | 1 | 2019 | 93 | 0.05 | Why? |
| Metabolic Clearance Rate | 1 | 2018 | 110 | 0.05 | Why? |
| Hospitals | 1 | 2018 | 11793 | 0.05 | Why? |
| Asthma | 1 | 2017 | 4383 | 0.05 | Why? |
| Edema, Cardiac | 1 | 2017 | 33 | 0.05 | Why? |
| Insulin-Like Growth Factor Binding Proteins | 1 | 2018 | 35 | 0.04 | Why? |
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2018 | 45 | 0.04 | Why? |
| Spectroscopy, Near-Infrared | 1 | 2019 | 137 | 0.04 | Why? |
| Far East | 1 | 2018 | 125 | 0.04 | Why? |
| Advanced Cardiac Life Support | 1 | 2017 | 75 | 0.04 | Why? |
| Calorimetry, Indirect | 1 | 2017 | 49 | 0.04 | Why? |
| Galectin 3 | 1 | 2018 | 76 | 0.04 | Why? |
| Kaplan-Meier Estimate | 2 | 2018 | 4260 | 0.04 | Why? |
| Cardiovascular Diseases | 3 | 2017 | 11497 | 0.04 | Why? |
| Aftercare | 2 | 2017 | 1637 | 0.04 | Why? |
| Age Factors | 1 | 2019 | 21039 | 0.04 | Why? |
| Biomedical Research | 1 | 2018 | 5270 | 0.04 | Why? |
| Oxidoreductases | 1 | 2018 | 136 | 0.04 | Why? |
| Unfolded Protein Response | 1 | 2018 | 134 | 0.04 | Why? |
| Water-Electrolyte Balance | 1 | 2017 | 136 | 0.04 | Why? |
| Albumins | 1 | 2019 | 324 | 0.04 | Why? |
| Intraoperative Care | 1 | 2019 | 238 | 0.04 | Why? |
| Publication Bias | 1 | 2018 | 241 | 0.04 | Why? |
| Hypertension | 1 | 2019 | 8895 | 0.04 | Why? |
| Esophagus | 1 | 2019 | 139 | 0.04 | Why? |
| Narcotics | 1 | 2017 | 67 | 0.04 | Why? |
| Interleukin-7 | 1 | 2018 | 148 | 0.04 | Why? |
| Vena Cava, Inferior | 1 | 2017 | 103 | 0.04 | Why? |
| Protein Folding | 1 | 2018 | 270 | 0.04 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2018 | 6166 | 0.04 | Why? |
| District of Columbia | 1 | 2018 | 343 | 0.04 | Why? |
| Proof of Concept Study | 1 | 2019 | 696 | 0.04 | Why? |
| Blood Gas Analysis | 1 | 2020 | 893 | 0.04 | Why? |
| Cross Infection | 1 | 2018 | 8675 | 0.04 | Why? |
| Docosahexaenoic Acids | 1 | 2018 | 145 | 0.04 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 9335 | 0.04 | Why? |
| Systole | 1 | 2017 | 252 | 0.04 | Why? |
| Gene Deletion | 1 | 2018 | 430 | 0.04 | Why? |
| Bilirubin | 1 | 2019 | 503 | 0.04 | Why? |
| Lung | 3 | 2020 | 31049 | 0.04 | Why? |
| Human Experimentation | 1 | 2018 | 146 | 0.04 | Why? |
| Endoplasmic Reticulum Stress | 1 | 2018 | 253 | 0.04 | Why? |
| Inflammation | 1 | 2018 | 13255 | 0.04 | Why? |
| Analysis of Variance | 1 | 2018 | 950 | 0.04 | Why? |
| Blood Pressure Determination | 1 | 2019 | 450 | 0.04 | Why? |
| Pulmonary Gas Exchange | 1 | 2017 | 414 | 0.04 | Why? |
| Contraception | 1 | 2018 | 291 | 0.03 | Why? |
| Arteries | 1 | 2017 | 283 | 0.03 | Why? |
| Finland | 1 | 2017 | 671 | 0.03 | Why? |
| Sensitivity and Specificity | 3 | 2020 | 22971 | 0.03 | Why? |
| Aorta | 1 | 2017 | 355 | 0.03 | Why? |
| Lipopolysaccharides | 1 | 2018 | 848 | 0.03 | Why? |
| Longitudinal Studies | 2 | 2021 | 9893 | 0.03 | Why? |
| Nebulizers and Vaporizers | 1 | 2017 | 497 | 0.03 | Why? |
| Comorbidity | 4 | 2020 | 34796 | 0.03 | Why? |
| Drug Utilization | 1 | 2018 | 619 | 0.03 | Why? |
| Glycoproteins | 1 | 2018 | 615 | 0.03 | Why? |
| Programmed Cell Death 1 Receptor | 1 | 2018 | 724 | 0.03 | Why? |
| Cardiovascular Physiological Phenomena | 1 | 2013 | 70 | 0.03 | Why? |
| Calcium | 1 | 2018 | 708 | 0.03 | Why? |
| Mice, Knockout | 1 | 2018 | 1815 | 0.03 | Why? |
| Data Accuracy | 1 | 2018 | 715 | 0.03 | Why? |
| Chronic Disease | 2 | 2018 | 5139 | 0.03 | Why? |
| Infusions, Intravenous | 1 | 2017 | 1224 | 0.03 | Why? |
| Logistic Models | 2 | 2018 | 9089 | 0.03 | Why? |
| Weight Gain | 1 | 2017 | 552 | 0.03 | Why? |
| Healthy Volunteers | 1 | 2018 | 1444 | 0.03 | Why? |
| Prevalence | 3 | 2020 | 25773 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2019 | 2324 | 0.03 | Why? |
| Troponin T | 1 | 2017 | 771 | 0.03 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2020 | 2309 | 0.03 | Why? |
| Troponin | 1 | 2017 | 1058 | 0.03 | Why? |
| Interleukin-10 | 1 | 2018 | 1409 | 0.03 | Why? |
| Liver Function Tests | 1 | 2017 | 1325 | 0.03 | Why? |
| Escherichia coli | 1 | 2018 | 1547 | 0.03 | Why? |
| Mental Health | 1 | 2017 | 15770 | 0.03 | Why? |
| Demography | 1 | 2017 | 1660 | 0.02 | Why? |
| Regression Analysis | 1 | 2017 | 2484 | 0.02 | Why? |
| Patient Positioning | 1 | 2020 | 1505 | 0.02 | Why? |
| Severity of Illness Index | 4 | 2019 | 48226 | 0.02 | Why? |
| Health Expenditures | 1 | 2017 | 904 | 0.02 | Why? |
| Peptides | 1 | 2021 | 2513 | 0.02 | Why? |
| Mexico | 1 | 2017 | 2787 | 0.02 | Why? |
| Switzerland | 1 | 2017 | 2738 | 0.02 | Why? |
| Animals | 4 | 2018 | 78931 | 0.02 | Why? |
| Prone Position | 1 | 2020 | 1861 | 0.02 | Why? |
| Mice | 2 | 2018 | 21357 | 0.02 | Why? |
| Extracorporeal Membrane Oxygenation | 2 | 2020 | 5002 | 0.02 | Why? |
| Apoptosis | 1 | 2018 | 2335 | 0.02 | Why? |
| Pandemics | 5 | 2020 | 389249 | 0.02 | Why? |
| Oxidative Stress | 1 | 2018 | 2050 | 0.02 | Why? |
| Ventilator Weaning | 1 | 2012 | 536 | 0.02 | Why? |
| Recurrence | 1 | 2016 | 3675 | 0.02 | Why? |
| Quality Improvement | 1 | 2019 | 2435 | 0.02 | Why? |
| Oxygen | 1 | 2020 | 3715 | 0.02 | Why? |
| Oxygen Inhalation Therapy | 1 | 2020 | 3629 | 0.02 | Why? |
| Internationality | 1 | 2019 | 3297 | 0.02 | Why? |
| Phenotype | 1 | 2017 | 4037 | 0.02 | Why? |
| Gene Expression Regulation | 1 | 2018 | 4020 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2021 | 5993 | 0.02 | Why? |
| Myocardium | 1 | 2017 | 2323 | 0.02 | Why? |
| Electrocardiography | 1 | 2019 | 3957 | 0.02 | Why? |
| Hospitals, University | 1 | 2017 | 4173 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2019 | 7220 | 0.02 | Why? |
| Australia | 1 | 2017 | 6306 | 0.02 | Why? |
| Forecasting | 1 | 2018 | 4492 | 0.02 | Why? |
| Postoperative Complications | 1 | 2019 | 5861 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2018 | 10998 | 0.01 | Why? |
| Blood Coagulation | 1 | 2013 | 2768 | 0.01 | Why? |
| Socioeconomic Factors | 1 | 2017 | 8495 | 0.01 | Why? |
| Anticoagulants | 1 | 2020 | 9563 | 0.01 | Why? |
| Young Adult | 2 | 2018 | 93724 | 0.01 | Why? |
| United Kingdom | 1 | 2017 | 18046 | 0.01 | Why? |
| Pediatrics | 1 | 2012 | 2969 | 0.01 | Why? |
| China | 1 | 2020 | 50654 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2018 | 43792 | 0.01 | Why? |
| United States | 1 | 2017 | 46150 | 0.01 | Why? |
| Telemedicine | 1 | 2017 | 25032 | 0.00 | Why? |